Comparison of heart failure risk assessment tools among cancer survivors
- PMID: 39394611
- PMCID: PMC11468191
- DOI: 10.1186/s40959-024-00267-5
Comparison of heart failure risk assessment tools among cancer survivors
Abstract
Background: Cancer survivors have an increased risk of incident heart failure (HF) attributable to shared risk factors and cancer treatment-induced cardiac dysfunction. Selection for HF screening depends on risk assessment, but the optimal means of assessing risk is undefined. We undertook a comparison of HF risk calculators among survivors.
Methods: In this study from the UK Biobank, cancer and HF diagnoses were determined based on the International Classification of Diseases (ICD)-10 code and non-cancer participants were included as controls. Participants' risk of incident HF was determined using the Heart Failure Association-International Cardio-oncology Society (HFA-ICOS), the Atherosclerosis Risk in Communities (ARIC-HF) and the Pooled Cohort Equations to Prevent Heart Failure (PCP-HF). The predictive performances of each were compared using the area under the curve (AUC).
Results: After propensity matching with age and sex, 9,232 survivors from breast cancer or lymphoma (mean age 59.9 years, 87.8% female), and 23,800 survivors from other cancer types (mean age 59.1 years, 85.8% female) were included in the analysis. The discriminative value for HFA-ICOS (AUC 0.753 [95%CI: 0.739-0.766]) and ARIC-HF (0.757 [95%CI: 0.744-0.770]) were similar, and superior to PCP-HF (0.717 [95%CI: 0.702-0.732]). The overall performance for each risk score was better among participants in other cancer types than those with breast cancer and lymphoma.
Conclusions: HFA-ICOS and ARIC-HF outperformed the PCP-HF among cancer- and non-cancer cohort, although all showed modest discrimination for incident HF to be applied to clinical practice. A cancer-specific HF prediction tool could facilitate HF prevention among survivors.
Keywords: Cancer; Heart failure; Prognosis; Risk assessment.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
Use of Polygenic Risk Score for Prediction of Heart Failure in Cancer Survivors.JACC CardioOncol. 2024 Aug 30;6(5):714-727. doi: 10.1016/j.jaccao.2024.04.010. eCollection 2024 Oct. JACC CardioOncol. 2024. PMID: 39479322 Free PMC article.
-
Ten-Year Risk-Prediction Equations for Incident Heart Failure Hospitalizations in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort Study and the Multi-Ethnic Study of Atherosclerosis.J Card Fail. 2022 Apr;28(4):540-550. doi: 10.1016/j.cardfail.2021.10.007. Epub 2021 Nov 8. J Card Fail. 2022. PMID: 34763078 Free PMC article.
-
Association of Subclinical Heart Maladaptation With the Pooled Cohort Equations to Prevent Heart Failure Risk Score for Incident Heart Failure.JAMA Cardiol. 2021 Feb 1;6(2):214-218. doi: 10.1001/jamacardio.2020.5599. JAMA Cardiol. 2021. PMID: 33175083 Free PMC article.
-
Prediction models for heart failure in the community: A systematic review and meta-analysis.Eur J Heart Fail. 2023 Oct;25(10):1724-1738. doi: 10.1002/ejhf.2970. Epub 2023 Jul 31. Eur J Heart Fail. 2023. PMID: 37403669
-
Pharmacotherapy for Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Childhood Cancer Survivors.Paediatr Drugs. 2023 Nov;25(6):695-707. doi: 10.1007/s40272-023-00585-8. Epub 2023 Aug 28. Paediatr Drugs. 2023. PMID: 37639193 Review.
References
-
- Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Reviews Cardiol. 2015;12:547–58. - PubMed
-
- Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22:1945–60. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous